

Caltech | Funding Memo

Title: The Lawrence and Isabel Barnett Drug Development Program 2022 - LOI

Funding Agency: ALS Association

External Deadline(s):

03/30/2022 02:00 PM PDT (LOI)

06/01/2022 02:00 PM PDT (Full Proposal)

Cognizant Office: Office of Sponsored Research/Office of Foundation Relations

Description:

The ALS Association's Barnett Drug Development grant program supports preclinical drug discovery and development of new or repurposed treatments for amyotrophic lateral sclerosis (ALS). The Association seeks applications for the preclinical assessment of therapeutics for ALS that have a high probability of reaching the clinic within three years.

Frequency: Typically annual

Total Award: \$500,000

- The maximum total budget is \$500,000 (not more than \$250,000 per year, inclusive of both direct and indirect costs).
 - Economy travel up to \$2,000 per year to attend scientific conferences.
 - Moveable equipment costs not to exceed 20 percent of the annual budget.
 - Computer hardware and software costs up to \$2,000.
 - Recurring annual cost-of-living/inflationary increase up to 3% for personnel and consumable supplies.
 - Salary and wages and fringe benefits of personnel other than the salary of the Principal Investigator are allowed.
 - Salary and wages and fringe benefits of the Principal Investigator are allowed only when indirect costs are waived.
 - Direct salary for individuals not to exceed the salary limitation for Executive Level II of the Federal Executive pay scale provided at https://grants.nih.gov/grants/policy/salcap_summary.htm.
- Please see the [Grants Policy Statement](#) for additional cost allowability details (section 7.5).

Indirect Costs: 10% of Direct Costs

- **Caltech's minimum overhead rate is based on the award's annual gross funding. Please refer to the [FY22 Annual Rate Memo](#) for applicable minimum overhead requirements. Applicants must work within their division to account for the required overhead via an approved MORA form.**

Duration: Up to 2 years

- Anticipated earliest start date is August 2022.

Discipline(s): Biology and Biological Engineering; Chemistry and Chemical Engineering; Engineering and Applied Science

Eligibility: Research Faculty, Tenure-Track Faculty, Tenured Faculty

- Caltech researchers other than tenure-track faculty will need to obtain approval from the Division Chair and Vice Provost for Research prior to submitting an application.
- Postdoctoral fellows are not eligible to apply as a PI.
- The preclinical drug development process often requires resources beyond those available at a single organization. Therefore, applications are open to investigators participating in synergistic collaborations focused on testing and developing lead agents for the treatment of ALS.
 - If a collaboration is proposed, letters confirming/supporting the collaboration are required.

Research Areas of Interest:

- Both novel programs and repurposing of approved or clinically safe therapies from other disease indications are appropriate for this RFA. Studies can be performed by a contract research organization in collaboration with the PI.
- ALS Association is especially interested in drug discovery projects supporting the following:
 - In vivo efficacy testing of therapeutic candidates (pharmacological treatments, biological therapies, or gene therapy) in models of ALS.
 - Studies on pharmacokinetics, pharmacodynamics, preclinical toxicology/safety (ADME/Tox), dose-range finding, and target engagement.
 - Other IND enabling studies.
- Successful applications will provide strong and compelling data supporting the biological rationale for the proposed treatment and a clear plan, including essential "Go/No-Go" decision milestones, for moving the approach through the essential stages of development.

Research Exclusions:

- Clinical trials will not be supported with this funding opportunity.
- Early drug discovery studies proposing high-throughput screening, hit-to-lead, and lead optimization will also not be supported through this funding opportunity.

Post-Award Obligations:

- The Grantee will be required to submit semi-annual Research Progress Reports and annual Grant Expenditure Reports during the period of an award unless otherwise noted in the Agreement.

Recent Caltech Recipients:

- None

Guidelines & Other Information:

Overview: <https://www.als.org/research/funding-opportunities/lawrence-and-isabel-barnett-drug-development-program-2022>

Guidelines: https://www.als.org/sites/default/files/2022-02/Barnett%20RFA%20Document_2022_FINAL.pdf

ALS Grants Policy Statement: <https://www.als.org/sites/default/files/2021-03/ALS%20Association%20Grants%20Policy%20Statement%203-22-2021.pdf>

Prior Grantees (Searchable Database): https://proposalcentral.com/Insights/8tcjbJ1-_G4=/Public/Index

Please notify the Foundation Relations team if you anticipate making a submission or if you have any questions regarding this opportunity. We are here to help ensure that Caltech's proposals are competitive. We can assist with proposal development and advise you on the routing of your paperwork. Interested researchers should work with their division grant manager to prepare the budget, the MORA form, and the Division Approval Form (DAF). Submissions and awards for this grant program will be processed through the Office of Sponsored Research.

Opportunity ID: 1059